BridgeMD
Compares treatment options for Acute Heart Failure (AHF)
Official title Restrictive Versus Liberal Fluid Intake in Acute Decompensated Heart Failure
ClinicalTrials.gov ID: NCT07400991
What this study is testing
- What it's testing
- The aim of this clinical trial is to learn whether a thirst-driven, liberal fluid-intake strategy is comparable to a fluid-restriction strategy in patients hospitalized for acute decompensated heart failure (ADHF). The study will also assess the safety of the intervention and its effects on thirst and quality of life.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \>18 years
- Hospitalized for ADHF as the primary diagnosis, meeting both of the following:
- ≥1 documented symptom of new or worsening heart failure (dyspnea, fatigue, decreased exercise tolerance, or symptom of end-organ hypoperfusion).
- Objective evidence of ADHF, defined as either: i. ≥2 physical signs (edema, ascites, pulmonary rales/crackles, increased JVP, S3 gallop, rapid weight...
- Treatment with ≥40 mg IV furosemide (or equivalent)
You likely can't join if
- Requirement at admission for ICU-level care, or IV inotropic/vasopressor therapy for ADHF.
- Na+ \ 145 mmol/L.
- End-stage chronic kidney disease on chronic dialysis or eGFR \<15 mL/min/1.73 m2
- Any condition which would make participation unsafe or substantially affect protocol adherence, as judged by investigator.
See the full eligibility criteria
- Age \>18 years
- Hospitalized for ADHF as the primary diagnosis, meeting both of the following:
- ≥1 documented symptom of new or worsening heart failure (dyspnea, fatigue, decreased exercise tolerance, or symptom of end-organ hypoperfusion).
- Objective evidence of ADHF, defined as either: i. ≥2 physical signs (edema, ascites, pulmonary rales/crackles, increased JVP, S3 gallop, rapid weight gain due to fluid retention), OR ii. ≥1 physical sign AND ≥1...
- Treatment with ≥40 mg IV furosemide (or equivalent)
- Enrolment within 24 hours of admission
- Ability to provide informed consent
- Requirement at admission for ICU-level care, or IV inotropic/vasopressor therapy for ADHF.
- Na+ \ 145 mmol/L.
- End-stage chronic kidney disease on chronic dialysis or eGFR \<15 mL/min/1.73 m2
- Any condition which would make participation unsafe or substantially affect protocol adherence, as judged by investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Herning, Denmark
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Herning, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.